The founder of a volatility-hedging program that gained 3,700% in the March crash says 'the opportunity is ripe' for another chaotic market event — and shares how investors can take advantage of it.

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. Rob Emrich is the founder of the $411 million Acruence Capital. Acruence CapitalRob Emrich is the founder of the $411 million Acruence Capital, which offers various option overlay and volatility hedging strategies.  The firm's volatility capture program, which helps dampen volatility in their clients' portfolios, was up over 3,700% in March 2020 in the depth of the stock market crash.  Emrich is now suggesting that the VIX could hit 125 in the next 4-6 months given an unexpected catalyst that could be related to the elections, COVID-19, or geopolitical risks. He shares how investors can take advantage of this level of volatility and mitigate risks in their portfolios in preparation for what the options market is suggesting could be "a contested election." Visit Business Insider's homepage for more stories. When market volatility, as measured by the Cboe Volatility Index or VIX, hit an all-time high of 82.69 on March 16, Rob Emrich's phones were ringing off the hook.  In 2017, Emrich, the founder of Acruence Capital, had launched a "volatility capture program," which is aimed at capturing both rare market events and everyday spikes in volatility.  "When I built the volatility program, it was modeled for the VIX to hit To keep reading about The founder of a volatility-hedging program that gained 3,700% in the March crash says 'the opportunity is ripe' for another chaotic market event — and shares how investors can take advantage of it., Click on the link. Seoul, Korea
http://dlvr.it/RkZWDM

Comments

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Coronavirus Hasn't Diminished Tech Stocks' Allure

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint